PolyGenyx Snares $1M SBIR Help for Haplotyping | GenomeWeb

NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.

The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.